WASHINGTON--The Biotechnology Innovation Organization (BIO) has officially named Dr. J. Craig Venter as the recipient of its 2016 George Washington Carver Award for innovation in industrial biotechnology. The award honors the legacy of George Washington Carver, who was one of the founding fathers of the chemurgy movement, a branch of applied chemistry focused on manufacturing industrial products from raw agricultural materials. Industrial biotechnology is the modern-day equivalent of Carver’s vision for chemurgy, and the annual award honors an individual for carrying on Carver’s legacy.
“It is an honor to receive the prestigious George Washington Carver Award from BIO and to be represented among such an esteemed group of past winners. Synthetic Genomics and Synthetic Biology have the opportunity to profoundly impact food, pharmaceutical, and chemical manufacturing and I am pleased that by accepting this award it can help draw attention to that potential,” said Dr. Venter.
“BIO is pleased to recognize Dr. Venter for his determination to provide innovative biotech solutions to some of today’s greatest challenges in energy, nutrition, and medicine. Like George Washington Carver, Dr. Venter has developed technology that enables sustainable economic growth through use of renewable resources. Dr. Venter’s innovative achievements can help us meet global energy and nutrition needs while tackling the problem of global climate change resulting from increasing greenhouse concentrations in the atmosphere,” said Brent Erickson, Executive Vice President for BIO’s Industrial & Environmental Section.
“Dr. Venter’s commitment to this industry matches that of George Washington Carver. Throughout his career, he has used his vast knowledge of biotechnology to break through barriers in science and medicine that were once thought to be impenetrable. This makes him worthy of the recognition attached to this award,” said Joe Hrdlicka, Executive Director of the Iowa Biotechnology Association and sponsor of this year’s award.
Dr. Craig Venter will receive the award and give a plenary session talk at the upcoming BIO World Congress on Industrial Biotechnology plenary luncheon session on April 18, 2016 at the San Diego Convention Center in San Diego, California. A special selection committee chose him for opening new outlooks on impactful applications in a biobased economy and for industrial sustainability.
Dr. Venter’s contributions to the sequencing of Haemophilous influenzae in 1995 and of the human genome in 2000 stand as two major milestones of biology’s new era and illustrate how he transformed the biological sciences from a concept-driven scientific pursuit into a tool-driven scientific revolution.
In 2010, Venter furthered the new field of synthetic biology when his team at the J. Craig Venter Institute (JCVI) synthesized the first self-replicating bacterial cell of Mycoplasma mycoides. More recently, he and his team are working to create a “minimal cell,” which will serve as the work-horse of unimaginable industrial applications. Synthetic biology is an important new tool in the continued development of green chemistry, bio-based products, and sustainable chemicals and fuels. Venter also pioneered genomic work in the field of energy from algae that has contributed to knowledge about the challenges in developing economical and scalable algae biofuels.
As an academic scientist and an entrepreneur, Dr. Venter has formed and led several organizations including The Institute for Genomic Research (TIGR), JCVI, Synthetic Genomics Inc. (SGI), and his most recent company Human Longevity Inc. which promises to revolutionize health care practices and delivery. In all his undertakings he has formed and led multiple teams that have risen to the scientific challenges because of his unique abilities to motivate and inspire.
Past recipients of the Carver Award are Jonathan S. Wolfson, CEO, Solazyme in 2015; Ellen Kullman, CEO & Chair of the Board, DuPont in 2014; Dr. Jay Keasling, Hubbard Howe Jr., Distinguished Professor of Biochemical Engineering at the University of California, Berkeley in 2013; Steen Riisgaard, president and CEO of Novozymes in 2012; Gregory Stephanopoulos, the Willard Henry Dow Professor of Chemical Engineering at Massachusetts Institute of Technology in 2010; Charles O. Holliday, Jr., chairman of the board of DuPont in 2009; and Dr. Patrick Gruber, CEO of Gevo, Inc., in 2008.
All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
April 4-6, 2016
World Congress on Industrial Biotechnology
April 17-20, 2016
San Diego, CA
BIO International Convention
June 6-9, 2016
San Francisco, CA
13th Annual BIO Asia International Conference
March 15-16, 2016